8-K: Syros Pharmaceuticals Faces Nasdaq Delisting Threat After Share Price and Market Value Fall Below Minimum Requirements

Syros Pharmaceuticals has received notices from Nasdaq for failing to meet minimum bid price and market capitalization requirements, placing its listing status at risk.

Summary

• Syros Pharmaceuticals received deficiency letters from Nasdaq because its stock price closed below $1.00 for 35 consecutive days.
• The company's market value of listed securities (MVLS) has been below $50 million for 30 consecutive business days.
• The market value of publicly held shares (MVPHS) has been below $15 million for 35 consecutive business days.
• Syros has 180 days, until July 7, 2025, to regain compliance with these listing requirements.
• To regain compliance, the stock price must close at or above $1.00 for at least ten consecutive business days.
• The MVLS must close at or above $50 million for at least ten consecutive business days.
• The MVPHS must close at or above $15 million for at least ten consecutive business days.
• If Syros fails to regain compliance, it may face delisting from the Nasdaq Global Select Market.
• Syros may be eligible for an additional 180-day compliance period for the minimum bid price requirement by transferring to the Nasdaq Capital Market.
• Transferring to the Nasdaq Capital Market requires meeting other listing standards and paying an application fee.
• There is no guarantee that Syros will regain compliance or successfully transfer to the Nasdaq Capital Market.

Sentiment

Score: 3

Explanation: The document indicates significant negative news regarding the company's listing status, which is a major concern for investors. The company is facing potential delisting, which is a serious issue.

Positives

• Syros has 180 days to regain compliance with Nasdaq listing requirements.
• The company has the option to transfer to the Nasdaq Capital Market for an additional 180-day compliance period for the minimum bid price requirement.

Negatives

• Syros's stock price has fallen below the minimum bid price of $1.00 per share.
• The company's market value has dropped below the required minimums for continued listing on the Nasdaq Global Select Market.
• There is no guarantee that Syros will regain compliance with the listing requirements.
• The company faces potential delisting from the Nasdaq Global Select Market if it fails to regain compliance.

Risks

• Syros faces the risk of being delisted from the Nasdaq Global Select Market if it does not regain compliance with the listing requirements.
• There is no guarantee that the company will be able to increase its stock price or market capitalization to meet the minimum requirements.
• Transferring to the Nasdaq Capital Market is not guaranteed and requires meeting other listing standards and paying an application fee.
• The company's stock price and market value may continue to decline if it fails to regain compliance.

Future Outlook

Syros intends to actively monitor the listing requirements and evaluate available options to regain compliance, including a potential transfer to the Nasdaq Capital Market. However, there is no assurance that the company will be successful in these efforts.

Management Comments

• Syros intends to actively monitor each of the Listing Requirements and evaluate available options to regain compliance with all of them.
• There can be no assurance that Syros will be able to regain compliance with any Listing Requirement.

Industry Context

This announcement highlights the challenges faced by biotech companies with fluctuating stock prices and market valuations. It is not uncommon for companies in this sector to face delisting risks if they fail to meet minimum listing requirements.

Comparison to Industry Standards

• Many biotech companies, especially those in the development stage, face similar challenges with maintaining minimum listing requirements.
• Companies like Agenus Inc. (AGEN) and Cellectar Biosciences (CLRB) have also faced delisting notices in the past due to low stock prices.
• The Nasdaq minimum bid price requirement of $1.00 is a common hurdle for smaller biotech firms.
• The market capitalization requirements are also standard for maintaining a listing on major exchanges.
• Syros's situation is not unique, but it underscores the importance of maintaining investor confidence and achieving clinical and commercial milestones to support stock value.

Stakeholder Impact

• Shareholders face the risk of losing their investment if the company is delisted.
• Employees may experience uncertainty about the company's future.
• The company's reputation and ability to attract future investment may be negatively impacted.

Next Steps

• Syros will monitor its stock price and market capitalization to regain compliance with Nasdaq listing requirements.
• The company will evaluate options to regain compliance, including a potential transfer to the Nasdaq Capital Market.
• Syros may appeal a delisting determination to a Nasdaq Listing Qualifications Panel if necessary.

Key Dates

Keywords

Nasdaq, delisting, minimum bid price, market capitalization, listing requirements, compliance, SYRS, Nasdaq Global Select Market, Nasdaq Capital Market